Novel anti-inflammatory androstane derivative
AssigneeSmithKline Beecham Corporation
InventorKeith Biggadike
Life of this patent
Estimating the term…
Abstract
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), 1 or a solvate thereof, together with a long-acting β2-adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.
Claims18
A pharmaceutical formulation for administration by inhalation comprising a compound of formula (I),
- 26
- or a solvate thereof, together with a long-acting β2-adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.
An inhaler containing a plurality of doses of a pharmaceutical formulation comprising a compound of formula (I)
- 27
- or a solvate thereof, together with a long-acting β2-adrenoreceptor agonist, which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more, and which doses are suitable for once-per-day administration of the formulation by inhalation.
An inhaler containing a plurality of doses of a pharmaceutical formulation comprising a particulate compound of formula (I)
- 28
- or a solvate thereof, a particulate long-acting β2-adrenoreceptor agonist and a carrier, each drug being present in an amount adequate to provide a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more following once-per-day dosing by inhalation.
Dependencies are inferred from the claim text.